BioVie has postponed plans for an initial public offering (IPO) valued at as much as $15 million, as reported NASDAQ Tuesday.
In the IPO, the company planned to offer 1.3 million shares at $11.44 per share.
FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>
To read more NewsPoints articles, click here.
